thromboplastin and Budd-Chiari-Syndrome

thromboplastin has been researched along with Budd-Chiari-Syndrome* in 2 studies

Other Studies

2 other study(ies) available for thromboplastin and Budd-Chiari-Syndrome

Article	Year
Fatal thrombosis of antithrombin-deficient mice is rescued differently in the heart and liver by intercrossing with low tissue factor mice. Journal of thrombosis and haemostasis : JTH, 2006, Volume: 4, Issue:1 We previously reported that the targeted disruption of murine antithrombin (AT) gene resulted in embryonic lethality before 16.5 gestational days (gd) because of severe cardiac and hepatic thrombosis.. To investigate the influences of lowered tissue factor (TF) activity upon hypercoagulation of AT-/- embryos, we crossed AT+/- with low TF (mTF-/- hTF+) mice to yield homozygous AT-deficient mice with the extremely low TF activity, that is expressed from the inserted human TF mini gene.. AT-/- embryos either with 50% TF (AT-/- mTF+/- hTF+) or with low (approximately 1% TF, AT-/- mTF-/- hTF+) were not born, although the survival was prolonged until 18.5 gd. In both genotypes, histological examination showed disseminated thrombosis in hepatic sinusoidal space or in the portal veins, suggesting that the thrombogenesis caused loss of hepatic blood flow. As in original AT-/-, AT-/- mTF+/- hTF+ showed subcutaneous (s.c.) bleeding and also suffered from the myocardial degeneration apparently because of coronary thrombus formation. However, AT-/- mTF-/- hTF+ had no skin hemorrhage and the thrombosis and degeneration were completely abolished in the heart. Myocardium of adult low TF mice had exhibited fibrosis secondary to hemorrhage; however, it was significantly decreased in low TF mice with AT+/-.. Our current model suggests that, in the heart, TF plays an important role in the thrombogenesis and it counterbalances AT-dependent anticoagulation. AT may be a potent anticoagulant during mice development and the activation and subsequent regulation of TF-procoagulant activity take place differently between the liver and the heart. These differences appear to point to local regulatory mechanisms in murine hemostasis. Topics: Animals; Antithrombin III; Budd-Chiari Syndrome; Coronary Thrombosis; Embryo, Mammalian; Hemorrhage; Hemostasis; Humans; Liver; Mice; Mice, Knockout; Mice, Transgenic; Myocardium; Thromboplastin; Thrombosis	2006
[A case of Budd-Chiari syndrome with lupus anticoagulant]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 1985, Volume: 26, Issue:8 Topics: Adult; Blood Coagulation Factors; Budd-Chiari Syndrome; Female; Fibrinolysis; Humans; Lupus Coagulation Inhibitor; Thromboplastin	1985

Article

Year

Fatal thrombosis of antithrombin-deficient mice is rescued differently in the heart and liver by intercrossing with low tissue factor mice.

Journal of thrombosis and haemostasis : JTH, 2006, Volume: 4, Issue:1

We previously reported that the targeted disruption of murine antithrombin (AT) gene resulted in embryonic lethality before 16.5 gestational days (gd) because of severe cardiac and hepatic thrombosis.. To investigate the influences of lowered tissue factor (TF) activity upon hypercoagulation of AT-/- embryos, we crossed AT+/- with low TF (mTF-/- hTF+) mice to yield homozygous AT-deficient mice with the extremely low TF activity, that is expressed from the inserted human TF mini gene.. AT-/- embryos either with 50% TF (AT-/- mTF+/- hTF+) or with low (approximately 1% TF, AT-/- mTF-/- hTF+) were not born, although the survival was prolonged until 18.5 gd. In both genotypes, histological examination showed disseminated thrombosis in hepatic sinusoidal space or in the portal veins, suggesting that the thrombogenesis caused loss of hepatic blood flow. As in original AT-/-, AT-/- mTF+/- hTF+ showed subcutaneous (s.c.) bleeding and also suffered from the myocardial degeneration apparently because of coronary thrombus formation. However, AT-/- mTF-/- hTF+ had no skin hemorrhage and the thrombosis and degeneration were completely abolished in the heart. Myocardium of adult low TF mice had exhibited fibrosis secondary to hemorrhage; however, it was significantly decreased in low TF mice with AT+/-.. Our current model suggests that, in the heart, TF plays an important role in the thrombogenesis and it counterbalances AT-dependent anticoagulation. AT may be a potent anticoagulant during mice development and the activation and subsequent regulation of TF-procoagulant activity take place differently between the liver and the heart. These differences appear to point to local regulatory mechanisms in murine hemostasis.

Topics: Animals; Antithrombin III; Budd-Chiari Syndrome; Coronary Thrombosis; Embryo, Mammalian; Hemorrhage; Hemostasis; Humans; Liver; Mice; Mice, Knockout; Mice, Transgenic; Myocardium; Thromboplastin; Thrombosis

2006

[A case of Budd-Chiari syndrome with lupus anticoagulant].

[Rinsho ketsueki] The Japanese journal of clinical hematology, 1985, Volume: 26, Issue:8

Topics: Adult; Blood Coagulation Factors; Budd-Chiari Syndrome; Female; Fibrinolysis; Humans; Lupus Coagulation Inhibitor; Thromboplastin

1985